Abbisko Therapeutics

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of ABSK091 and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations, as well as a licensing agreement with Sperogenix (Shanghai) MedTech Co., Ltd. to develop and commercialize ABSK021 for indications in non-oncology neurological rare diseases. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Our mission is to become a pioneering leader in the development and commercialization of innovative, safe, and cost-effective treatments of genetic diseases and cancer.

At Abbisko, we envisage a world where everyone has access to the latest healthcare treatments and innovations, regardless of background or economic status.

Abbisko Therapeutics has been recognized for its commitment to excellence in research and development, as well as for its dedication to making healthcare more accessible. We have won multiple awards like the Healthcare Innovation Award and the Biotech Achievement Award.